Raza Bokhari Destroyed FSD Pharma Dr. Bokhari and his collaborating directors are destroying Shareholder value. The Share price has declined by over 97% and the Company’s market capitalization has shrunk by over $500 million since Dr. Bokhari was appointed Interim Chief Executive Officer on October 29, 2018.
During this time, Dr. Bokhari and his collaborating directors have attempted to refocus the Company as an early-stage pharmaceutical and biotechnology venture. Yet, they have failed
to achieve any of its stated goals, deferred holding a Shareholder meeting and actively obstructed two founding directors who have questioned Dr. Bokhari’s leadership and the complacency of his collaborating directors.
The collaborating directors have enabled Dr. Bokhari despite his poor performance and have disregarded his misconduct, including threatening two of the Concerned Shareholders and taking actions that have gratuitously exposed the Company to legal actions.
The Concerned Shareholders have taken action at their personal expense to compel the Company to hold the Meeting in a timely and fair fashion to elect directors who will address the continued erosion of Shareholder.
The Board’s ineffective oversight of management and outrageous self-awards of bonus compensation are accelerating the Company’s decline and must be stopped. This utter failure to address the Company’s urgent needs, or even achieve stated goals, has been compounded by recent misconduct of the collaborating directors and management.
Shareholders are urged to read the Circular and also monitor the Concerned Shareholders’ press releases and other filings at
www.RestoreFSD.com to ensure they have all the information they require to take necessary action within the prescribed time periods in order to show their support for the Concerned Shareholders’ proposed changes to the Board.